全文获取类型
收费全文 | 298187篇 |
免费 | 72090篇 |
国内免费 | 8488篇 |
专业分类
耳鼻咽喉 | 6561篇 |
儿科学 | 9695篇 |
妇产科学 | 3582篇 |
基础医学 | 26733篇 |
口腔科学 | 7545篇 |
临床医学 | 47481篇 |
内科学 | 77130篇 |
皮肤病学 | 14681篇 |
神经病学 | 29113篇 |
特种医学 | 11324篇 |
外国民族医学 | 53篇 |
外科学 | 60992篇 |
综合类 | 15737篇 |
现状与发展 | 97篇 |
一般理论 | 28篇 |
预防医学 | 16250篇 |
眼科学 | 6624篇 |
药学 | 15032篇 |
88篇 | |
中国医学 | 6767篇 |
肿瘤学 | 23252篇 |
出版年
2024年 | 1033篇 |
2023年 | 6040篇 |
2022年 | 4750篇 |
2021年 | 8694篇 |
2020年 | 14405篇 |
2019年 | 15448篇 |
2018年 | 18329篇 |
2017年 | 19600篇 |
2016年 | 20825篇 |
2015年 | 22216篇 |
2014年 | 30151篇 |
2013年 | 30400篇 |
2012年 | 15369篇 |
2011年 | 15924篇 |
2010年 | 22540篇 |
2009年 | 22072篇 |
2008年 | 11803篇 |
2007年 | 8917篇 |
2006年 | 11347篇 |
2005年 | 8135篇 |
2004年 | 6077篇 |
2003年 | 5057篇 |
2002年 | 4863篇 |
2001年 | 6321篇 |
2000年 | 5357篇 |
1999年 | 5057篇 |
1998年 | 4677篇 |
1997年 | 4428篇 |
1996年 | 4088篇 |
1995年 | 3901篇 |
1994年 | 2500篇 |
1993年 | 1967篇 |
1992年 | 1829篇 |
1991年 | 1844篇 |
1990年 | 1340篇 |
1989年 | 1402篇 |
1988年 | 1267篇 |
1987年 | 1060篇 |
1986年 | 1014篇 |
1985年 | 813篇 |
1984年 | 624篇 |
1983年 | 561篇 |
1982年 | 545篇 |
1981年 | 438篇 |
1980年 | 383篇 |
1979年 | 351篇 |
1978年 | 343篇 |
1977年 | 407篇 |
1975年 | 288篇 |
1972年 | 313篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
Vincent Chung Liang Liu Zhaoxiang Bian Zhongzhen Zhao Wai Leuk Fong Wan Fung Kum Jing Gao Min Li 《Movement disorders》2006,21(10):1709-1715
The objective of this study is to assess the efficacy and safety of herbal medicines (HMs), as a monotherapy or adjunct therapy, compared to placebo or conventional approaches in the treatment of idiopathic Parkinson's disease (PD). We conducted a systematic review of randomized controlled trials from both conventional and alternative medicine sources. Outcome measures were overall improvement, quality of life, reduction of levodopa dose, and adverse events. Nine studies were included, each testing a different HM. Six of the trials had limited internal validity due to major flaws in design, including the lack of proper randomization; insufficient blinding; unclear inclusive criteria in terms of diagnostic criteria, baseline staging, and duration of disease; lack of proper sample size calculation; and insufficient data analysis. Imbalances in gender and ethnicity among the patients in the included trials were observed. No major adverse events emerged, and no specific pattern was detected from the trials describing such data. In addition to major methodological defects, heterogeneity in (1) HM tested, (2) control treatment, and (3) outcome measure hindered in-depth data analysis and synthesis. Current evidence is insufficient to evaluate the efficacy and safety of various HMs. Further studies with improved trial design and reporting, with assessment on cost-effectiveness, quality of life, and qualitative data are warranted. 相似文献
54.
55.
56.
Prostatitis and male infertility are frequent disorders, and the role of prostatitis in male infertility has been under discussion for more than 30 years. Many researchers have shown relevant links between the two. Although a causal relationship has not been definitely demonstrated, increasing evidence shows that chronic prostatitis has a relevant negative impact on male fertility potential, at least in certain subgroups. In the following review, we focus on the present state of knowledge on the role of chronic prostatitis as an etiologic factor in male infertility. 相似文献
57.
J. Curtis Nickel MD 《Current Prostate Reports》2006,4(3):132-137
Medical therapy is currently the most popular treatment choice for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Because medical therapy of BPH-related LUTS is considered a life-long strategy, short- and long-term cost considerations should play a major role in therapeutic decision-making. The effectiveness in terms of long and short amelioration of symptoms, flow rate, and quality of life are well documented for 5α-blockers and 5α-reductase inhibitors as well as for the gold standard treatment for BPH, transurethral resection of the prostate and minimally invasive therapies. Short-and long-term safety concerns also are well documented for these various treatment options. On the contrary, short- and long-term costs have been less well studied and comparisons depend on the model or analyses undertaken in the few studies available. However, the economic studies based on prospective clinical trial data that have become available throughout the past several decades allow us to rationalize our use of α-blockers, 5α -reductase inhibitors, and combination therapy, taking into consideration age, severity of symptoms, prostate volume, prostate-specific antigen, and the differential response of the various medications (and combination) in selected patients. Based on current studies, 5α -blockers generally provide cost-effective therapy for most patients, whereas 5α-reductase therapy and combination therapy provide cost-effective treatment for patients with larger prostate glands or higher baseline prostate-specific antigen levels. 相似文献
58.
59.
Abstract: Background: Identification of risk drinking in expectant fathers may be helpful as an important part of efforts to minimize maternal alcohol use, and as an opportunity to inform them about a problematic practice during a critical developmental stage for the couple. The purpose of this study was to evaluate the T‐ACE screening questionnaire, which asks about t olerance to alcohol, being a nnoyed by other's comments about drinking, attempts to c ut down, and having a drink first thing in the morning (“ e ye‐opener”), in the male partners of pregnant women who themselves were T‐ACE positive. Methods: Two hundred fifty‐four male partners were asked to complete the T‐ACE embedded in a health survey, the Alcohol Use Disorders Identification Test (AUDIT), and other questions about their alcohol use in the past 30 days when their pregnant partners had a median gestation of 11.5 weeks (T1). After delivery, male partners again completed the T‐ACE and quantity‐frequency questions (T2). The predictive ability of the T‐ACE and AUDIT was compared, using risk drinking (>4 drinks/day or >14 drinks/week) as the criterion standard. Results: A substantial minority of male partners had risk drinking, 31 percent at T1 and 25 percent at T2. Although the AUDIT was better than the T‐ACE as an independent predictor of risk drinking, the latter was most accurate when the tolerance threshold exceeded 2 drinks, the same established for pregnant women. The sensitivity (T1 = 84.6%, T2 = 82.8%) and specificity (T1 = 43.8%, T2 = 51.1%) of the T‐ACE at this threshold compared favorably with those of the AUDIT at the standard cut point of 8. Conclusions: The T‐ACE may be a practical way for clinicians to identify risk drinking in both pregnant women and expectant fathers. (BIRTH 33:2 June 2006) 相似文献
60.